Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735316 · ClinicalTrials.gov registry record · Phase 2
Vitamin B12a Vasoplegic Syndrome
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03735316: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT03735316 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03735316, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.
Primary Outcome
The average pressure in a patient's arteries during one cardiac cycle
Interventions
- DRUG Placebos
- DRUG Hydroxocobalamin
- PROCEDURE Cardiopulmonary Bypass
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 2 |
Why NCT03735316 stopped before completion
NCT03735316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT03735316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03735316 about?
NCT03735316 is a clinical study titled "Vitamin B12a Vasoplegic Syndrome". The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.
What is the current status of trial NCT03735316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-04-25. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03735316?
The interventions under investigation include: Placebos (DRUG), Hydroxocobalamin (DRUG), Cardiopulmonary Bypass (PROCEDURE).
Who is sponsoring clinical trial NCT03735316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03735316's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI